Zahir H. Alshehry
Zahir H. Alshehry
Consultant Clinical Scientist, Biochemist Head of Biochemistry Laboratory Pathological and Clinical Laboratory Medicine Administration (PCLMA) King Fahad Medical City,
Verified email at kfmc.med.sa
Title
Cited by
Cited by
Year
Plasma lipidomic profiles improve on traditional risk factors for the prediction of cardiovascular events in type 2 diabetes mellitus
ZH Alshehry, PA Mundra, CK Barlow, NA Mellett, G Wong, MJ McConville, ...
Circulation 134 (21), 1637-1650, 2016
942016
An efficient single phase method for the extraction of plasma lipids
ZH Alshehry, CK Barlow, JM Weir, Y Zhou, MJ McConville, PJ Meikle
Metabolites 5 (2), 389-403, 2015
642015
Weight loss and exercise alter the high-density lipoprotein lipidome and improve high-density lipoprotein functionality in metabolic syndrome
AA Khan, PA Mundra, NE Straznicky, PJ Nestel, G Wong, R Tan, K Huynh, ...
Arteriosclerosis, thrombosis, and vascular biology 38 (2), 438-447, 2018
202018
Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention
PA Mundra, CK Barlow, PJ Nestel, EH Barnes, A Kirby, P Thompson, ...
JCI insight 3 (17), 2018
182018
Changes in plasma lipids predict pravastatin efficacy in secondary prevention
KS Jayawardana, PA Mundra, C Giles, CK Barlow, PJ Nestel, EH Barnes, ...
JCI insight 4 (13), 2019
12019
Plasma Lipidomic Profiles in Two Large Independent Cohorts Improve Upon Conventional Risk Factors to Predict Cardiovascular Events
PA Mundra, CK Barlow, PJ Nestel, EH Barnes, A Kirby, P Thompson, ...
Circulation 134 (suppl_1), A17413-A17413, 2016
12016
Changes in plasma lipid species following pravastatin treatment predict cardiovascular outcomes and represent a measure of the relative risk reduction in secondary prevention
P Meikle, KS Jayawardana, PA Mundra, PJ Nestel, EH Barnes, A Kirby, ...
EUROPEAN HEART JOURNAL 39, 399-399, 2018
2018
P1875 Changes in plasma lipid species following pravastatin treatment predict cardiovascular outcomes and represent a measure of the relative risk reduction in secondary prevention
P Meikle, KS Jayawardana, PA Mundra, PJ Nestel, EH Barnes, A Kirby, ...
European Heart Journal 39 (suppl_1), ehy565. P1875, 2018
2018
Plasma lipidomic profiles in two large independent cohorts improve upon conventional risk factors to predict cardiovascular events
P Meikle, P Mundra, C Barlow, P Nestel, E Barnes, A Kirby, P Thompson, ...
Atherosclerosis 263, e4-e5, 2017
2017
Decreases in plasma phosphatidylinositol species partially explain the reduction in cardiovascular events after pravastatin therapy in secondary prevention
P Meikle, C Barlow, P Nestel, E Barnes, A Kirby, P Thompson, D Sullivan, ...
Atherosclerosis 263, e239, 2017
2017
Decreases in Plasma Phosphatidylinositol Species Partially Explain the Reduction in Cardiovascular Events After Pravastatin Therapy in Secondary Prevention
PA Mundra, CK Barlow, PJ Nestel, EH Barnes, A Kirby, P Thompson, ...
Circulation 134 (suppl_1), A17485-A17485, 2016
2016
Plasma lipidomic profiles improve upon conventional risk factors to predict cardiovascular events
P Mundra, C Barlow, N Mellett, K Huynh, Z Alshehry, G Wong, B Kingwell, ...
Atherosclerosis 252, e263-e264, 2016
2016
The relationship between the plasma lipidome and cardiovascular disease outcomes in diabetes
ZH Alshehry
2015
Plasma Lipid Profiling to Predict Cardiovascular Events in Type 2 Diabetes
ZH Alshehry, G Wong, PA Mundra, CK Barlow, NA Mellett, S Zoungas, ...
Circulation 130 (suppl_2), A18688-A18688, 2014
2014
The system can't perform the operation now. Try again later.
Articles 1–14